

Challenge

- Target identification and validation are among the greatest challenges in drug discovery.
- > 90% of new medicines fail, often in late-stage development where the cost is greatest.
- Accurate and comprehensive mechanistic and genetic evidence in humans for causal links between targets and diseases has a significant impact on successful development of new medicines for patients. Generating and interpreting this evidence demands a diverse set of skills, backgrounds, data types and technologies, which do not exist today in any single entity.


Open Targets



[Open Targets](#) is an innovative, large-scale, multi-year, public-private partnership that uses human [genetics](#), genomics and other 'omics data to systematically identify and prioritize the best targets to safely and effectively treat rare and common diseases.

Key Technologies

- WTSI cell line collections
- Sequencing, NGS
- CRISPR gene editing
- Single cell methods
- iPS cell differentiation and phenotyping
- Organoid and 2D/3D tissue culture
- Large scale genomics and epigenomics
- Bioinformatics (AI/ML/DL) and HPC



Features

- > 80 interlinked [projects](#) in oncology, neurodegeneration, and immunity and inflammation
- Integrating cutting-edge experimental and [informatics approaches](#)
- Advised by a panel of leading international experts from academia and industry
- Expertise in key technologies (see image)

Commercial Opportunity

As a member, you have

- First and preferred access to Open Targets' data
- Benefits from a clear, rapid IP process
- Visibility of and access to all past and current projects
- Possibility to direct future research from your first day of membership
- Possibility to work with world leading teams and the vibrant scientific community on the Wellcome Genome Campus, thus enhancing in-house R&D capability and capacity
- Reputational benefits through partnership and open innovation.

EMBLEM

TECHNOLOGY TRANSFER GMBH

Boxbergering 107, 69126 Heidelberg, Germany

Dr. Birgit Kerber, Business Development Lead
Open Targets

kerber@embl-em.de

www.embl-em.de

Highlights

[Behan et al., 2019](#): Cancer therapeutic prioritization
[Schwartzentruber et al., 2021](#): New Alzheimer's risk genes

[Pacini et al., 2021](#): Genetic dependencies in cancer
[Soskic et al., 2019](#): Immune diseases drivers